Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an update.
Shanghai Fosun Pharmaceutical has completed the issuance of its second tranche of scientific and technological innovation bonds for 2025, amounting to RMB1 billion with a coupon rate of 2.70%. This issuance is part of a larger RMB4 billion medium-term note program, reflecting the company’s strategic focus on innovation and providing it with additional capital to enhance its operations and market positioning.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on scientific and technological innovation, offering a range of pharmaceutical products and services.
Average Trading Volume: 9,048,580
Technical Sentiment Signal: Hold
Current Market Cap: HK$72B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.